“…Risk factors for VTE in patients with cancer are mainly cancer sites, metastasis stage, hospitalisation, central venous catheters, surgery, systemic medical anticancer therapies, history of previous VTE, cardiovascular diseases, obesity, immobility, thrombocytosis, leucocytosis and high D-dimer level 4. For lung cancer, previous studies showed that risk factors that are associated with the development of VTE mainly comprise but not limited to metastatic disease, adenocarcinoma subtype, chemotherapy administration, emergency admission, weight, performance status (PS), C-reactive protein (CRP), prothrombin time (PT), D-dimer, body mass index (BMI), major vessel infiltration, tyrosine kinase inhibitor (TKI) genetic mutation, surgery, immune checkpoint inhibitor (ICI) therapy and central venous catheter (CVC) 9 13 17 19–24. Among the aforementioned factors, TKI genetic mutations, surgery and ICI therapy are the most noteworthy ones in recent years.…”